Trial Profile
To study eligibility for biologic therapies for severe asthma (SA) in a cohort of patients attending the Program for Control of Asthma (ProAR) in Bahia, Brazil
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Oct 2021
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary) ; Mepolizumab (Primary) ; Omalizumab (Primary) ; Reslizumab (Primary)
- Indications Allergic asthma; Asthma
- Focus Therapeutic Use
- 27 Oct 2021 New trial record